Alto Neuroscience(ANRO) - 2025 Q4 - Annual Results

Exhibit 99.1 Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights – Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – – External PAX-D study published in The Lancet Psychiatry demonstrated a 0.87 effect size for the core mechanism of ALTO-207; this effect represents a significantly larger effect size than current standard-of-care treatments – – AL ...